Takeda Oncology Executive and Leadership Team

Marcelo Barretta, the Chief Financial Officer at Takeda Oncology, directs all fiscal planning and resource allocation for the oncology specialty business unit. Barretta manages complex budgetary frameworks to support the development of advanced cancer therapies. By overseeing capital investments and financial risk assessment, the Chief Financial Officer ensures the sustainability of research pipelines. This leadership role involves close collaboration with global stakeholders to optimize operational efficiency across North American and international markets. Marcelo Barretta maintains strict adherence to regulatory financial standards while driving long-term growth initiatives. Through precise fiscal oversight, the Chief Financial Officer enables the organization to scale production capabilities effectively. Barretta secures the necessary funding to accelerate clinical trials, ultimately impacting the speed at which new treatments reach patients. This financial discipline remains central to the mission of delivering high-quality oncology solutions to the global medical community.

Rob Smith, the President at Takeda Oncology, directs the overarching strategic vision and operational execution for the oncology business unit. Smith oversees the development of innovative pharmaceutical products designed to address critical patient needs. By guiding the executive team, the President ensures that research and development efforts remain focused on high-impact oncology therapies. This leadership role involves managing relationships with global partners to expand market reach and improve patient access to life-saving treatments. Rob Smith drives organizational growth by fostering a culture of scientific excellence and operational agility. The President monitors competitive landscapes to maintain a strong market position for the company. Through strategic decision-making, Smith aligns internal resources with the goal of transforming cancer care. This executive leadership ensures that the organization consistently delivers value to patients and stakeholders while maintaining a robust pipeline of oncology innovations.

Teresa Bitetti, the Global President, Oncology Business Unit at Takeda Oncology, architects the worldwide commercial strategy for the entire oncology portfolio. Bitetti leads the expansion of therapeutic offerings into new international markets, ensuring that patients gain access to advanced cancer treatments. By overseeing global marketing and sales operations, the Global President, Oncology Business Unit drives revenue growth and market penetration. This leadership role involves collaborating with regional heads to tailor commercial approaches to specific healthcare environments. Teresa Bitetti maintains a focus on patient-centric outcomes, ensuring that the business unit delivers meaningful clinical benefits. Through strategic oversight of the oncology pipeline, the Global President, Oncology Business Unit supports the transition of research breakthroughs into commercial success. Bitetti manages complex stakeholder relationships to strengthen the brand presence of the company. This leadership ensures that the organization remains a leader in the global oncology pharmaceutical sector.

Christophe Bianchi, the President at Takeda Oncology, leads the strategic integration of clinical development and commercialization efforts for the oncology business unit. Bianchi oversees the execution of long-term growth strategies, focusing on the advancement of the oncology pipeline. By directing cross-functional teams, the President ensures that scientific innovation translates into tangible patient benefits. This leadership role involves managing high-level partnerships to enhance the research capabilities of the organization. Christophe Bianchi drives operational excellence by optimizing internal processes and resource allocation. The President monitors global market trends to identify new opportunities for therapeutic expansion. Through rigorous oversight, Bianchi ensures that the company maintains its commitment to developing high-quality oncology therapies. This leadership position requires a deep understanding of the pharmaceutical landscape to navigate complex regulatory and market challenges. Bianchi secures the future of the organization by fostering innovation and maintaining a focus on patient-centered outcomes.

Tawnee Friedrich, the Chief Of Staff, GMAO at Takeda Oncology, coordinates strategic initiatives across the Global Medical Affairs Oncology division. Friedrich aligns cross-functional teams to ensure seamless execution of medical communication and evidence generation strategies. By managing internal workflows, the Chief Of Staff, GMAO facilitates communication between clinical research departments and commercial leadership. This role involves streamlining operational processes to support the rapid deployment of oncology therapies. Tawnee Friedrich monitors project milestones to ensure alignment with the broader corporate mission of Takeda Oncology. Through effective organizational management, the Chief Of Staff, GMAO optimizes the delivery of medical insights to healthcare providers. Friedrich drives efficiency in global operations, ensuring that medical affairs activities remain consistent across diverse geographic regions. This leadership position requires constant evaluation of internal performance metrics to maintain high standards of excellence in patient-focused medical support.